Double Sterilization in Pharmaceuticals: The Impact of Annex 1 on Component Strategy

Since the 2022 revision of EU GMP Annex 1 came into effect in August 2023, sterile manufacturing strategy has become one of the most consequential decisions in injectable drug development. What was once a binary choice between aseptic processing and terminal sterilization is shifting toward a hybrid "double sterilization" model — purchasing pre-sterilized, ready-to-use elastomeric components and then applying terminal sterilization again after filling and final assembly.

This white paper examines what is driving that shift, what it means for component selection and sterilization method choice, and how pharmaceutical manufacturers can build validation strategies that meet Annex 1's increasingly risk assessment-based expectations.

Why double sterilization is gaining ground

Annex 1 places greater emphasis on demonstrable contamination control across the entire manufacturing pathway — not just in the finished product. Sterility assurance must be proven, not presumed. RTU components reduce upstream contamination risk; terminal sterilization addresses risks introduced during filling. Together, they create a stronger compliance position and a more defensible contamination control strategy.

Steam vs gamma in a double sterilization context

Steam and gamma remain the dominant sterilization methods for elastomeric components, but the decision between them is becoming more nuanced under double sterilization. Not all components respond equally to repeated sterilization — dynamic components such as syringe plungers are particularly sensitive to cumulative irradiation, which can affect break-loose and glide forces. Starting with steam-sterilized components provides greater flexibility when terminal gamma irradiation follows later.

Validation complexity and the QbD imperative

Every sterilization pathway creates a unique validation requirement. There is no universal shortcut: steam followed by gamma, gamma followed by gamma, and varying irradiation doses all generate separate data sets. Annex 1's Quality by Design philosophy means sterilization strategy must be an early design decision — not an afterthought — considered alongside component design, elastomer formulation, coatings, washing processes, and CCI validation.

Who this white paper is for

This report is designed for pharmaceutical and biotech professionals in regulatory affairs, quality assurance, packaging engineering, and manufacturing strategy who are evaluating or building Annex 1-compliant sterilization strategies for injectable drug products.